Pfizer announced positive results from the Phase 3 BREAKWATER trial evaluating its Braftovi-based regimen in patients with metastatic colorectal cancer harboring BRAF V600E mutations. The study met its primary endpoints, demonstrating statistically significant improvements in progression-free survival and objective response rates compared to standard chemotherapy, establishing a potential new treatment option for this patient population.
The BREAKWATER trial enrolled patients with previously untreated metastatic colorectal cancer carrying the BRAF V600E mutation, a genetic alteration present in approximately 5-10% of colorectal cancer cases. Braftovi, a BRAF inhibitor, was evaluated in combination with other agents against the current standard-of-care chemotherapy regimen. The achievement of both co-primary endpoints positions the regimen as a potential advancement for this molecularly defined subset of patients.
Pfizer intends to use these trial results to support regulatory submissions for the indicated patient population. The company plans to present detailed efficacy and safety data at upcoming medical conferences and with regulatory authorities. This development adds to Pfizer's oncology portfolio and reflects the ongoing shift toward targeted therapies for genetically defined cancer populations.